Bliss GVS Pharma Q3 FY26 results: 0.50 rupee interim dividend declared

Revenue Growth 20pctExceptional ItemResults View source PDF Explain this filing

BLISSGVS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.0%Reaction day

₹202.50

prior close

₹209.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.0%-0.0% vs market

Pharmaceuticals peers, median of 159sector+0.4%+0.6% vs sector

On the reaction day the stock moved in line with Nifty Microcap 250 and 0.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

+0.1

15m

-1.4

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.0+1.0-0.0+0.4+0.6

Next day

+5.9+0.5+5.4+0.2+5.7

+7.6-0.0+7.6-0.0+7.6

+6.7-1.5+8.2-1.2+7.9

+9.1-2.2+11.3-1.8+10.9

+14.3-1.2+15.5-1.8+16.1

+11.6-2.4+14.0-2.6+14.2

15d

+6.7-8.8+15.5-7.0+13.7

+9.9-8.3+18.2-5.1+15.0

+27.9-3.5+31.4-3.5+31.4

+34.8+6.4+28.4+2.8+32.0

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Bliss GVS Pharma board approved unaudited Q3 FY26 results. Consolidated Q3 revenue grew 21.5% to Rs 21,825 lakh from Rs 17,959 lakh. Q3 net profit rose to Rs 2,327 lakh vs Rs 2,094 lakh. Board declared 0.50 paisa interim dividend per share, record date Feb 18, 2026. Statutory auditor issued unmodified review report. Exceptional charge of Rs 251.37 lakh booked for new labour codes.

Likely market impact

Strong Q3 revenue growth over 20% and dividend declared. One-time exceptional charge for labour codes.